Business
Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373
SK bioscience submits application for NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for BLA, to South Korea's MFDS GAITHERSBURG, Md., Nov.
About this update from Novavax, Inc.
[{"type":"text","content":"SK bioscience submits application for NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for BLA, to South Korea's MFDS\n GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited (SK bioscience), a biotechnology company in South Korea, today announced the submission of a Biologics License Application (BLA) for Novavax' COVID-19 vaccine to South Korea's Ministry of Food and Drug Safety (MFDS). NVX-CoV2373, Novavax' recombinant nanoparticle COVID-19 vaccine with Matrix-M™ adjuvant, is the first protein-based COVID-19 vaccine to be submitted for BLA in Korea.\n\"Today's submission reflects the first BLA submission for full approval of our COVID-19 vaccine anywhere in the world, with more anticipated to follow,\" said Stanley C. Erck, President and Chief Executive Officer, Novavax. \"Our partnership with SK bioscience reinforces our shared commitment to global equitable access as we work together to deliver our COVID-19 vaccine, built on a proven, well-understood vaccine platform.\"\nIn collaboration with Novavax, SK bioscience initiated the rolling submission process for NVX-CoV2373 to the MFDS in April of this year. The completion of a BLA submission to the MFDS marks the final review stage for authorization of NVX-CoV2373 in Korea. \nNovavax and SK bioscience have an existing manufacturing and licensing collaboration that is intended to provide broad and equitable access to NVX-CoV2373 both in Korea and globally through the COVAX Facility. SK bioscience finalized an advance purchase agreement with the Korean government to supply 40 million doses of NVX-CoV2373 to South Korea earlier this year.\n\"Novavax' protein-based vaccine will be a new cornerstone in overcoming the COVID-19 pandemic,\" said Jaeyong Ahn, Chief Executive Officer, SK bioscience. \"We are proud to collaborate in process development and production of Novavax' COVID-19 vaccine candidate in South Korea and are committed to doing our part in the fight against COVID-19.\" \nNovavax recently announced authorization of its vaccine in Indonesia. The company also announced regulatory filings for its vaccine in the United Kingdom, Australia, New Zealand and Canada, as well as the com...